Mark Egerton appointed chairman of Panthera Biopartners

Panthera Biopartners, the UK’s leading Site Management Organisation (SMO) which runs commercial clinical trials for the pharmaceutical industry, has appointed Mark Egerton as chairman.

Mark brings extensive experience in the pharmaceutical industry across the UK and the US.

He is currently chairman of Newmarket Strategy and was previously chief executive of Quotient Sciences, where he oversaw significant growth and international expansion.

Mark said: “I am delighted to join the board of Panthera Biopartners.

"The management team has done an exceptional job in building the UK’s most successful SMO in only five years and is already working with ten of the top 12 pharmaceutical companies and seven of the top CROs.

"With the backing of LDC (the private equity arm of Lloyds Banking Group) and BGF (British Growth Fund), Panthera will now seek to further expand its operations in the UK and Europe”. 

Panthera Biopartners was founded in 2019 and has rapidly become a key partner for global pharmaceutical and biotech companies, supporting faster and more efficient patient recruitment across a growing network of dedicated clinical trial sites.